Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Patnaik · SciRah

Researcher profile · Semantic Scholar

A. Patnaik

Share profile

A. Patnaik — researcher profile on SciRah

h-index: 76
Works: 533
Citations: 35K

Most-cited papers

Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.
F. Meric-Bernstam, M. Beeram, E. Hamilton, D. Oh +19 more
2022The Lancet Oncology164 citations Open access
Semantic Scholar
Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
J. Harding, V. Moreno, Y. Bang, M. Hong +15 more
2021Clinical Cancer Research127 citations Open access
Semantic Scholar
Brief Report: Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.
M. Awad, S. Gadgeel, H. Borghaei, A. Patnaik +14 more
2020Journal of Thoracic Oncology114 citations Open access
Semantic Scholar
Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
David S. Hong, M. Postow, B. Chmielowski, R. Sullivan +13 more
2023Clinical Cancer Research93 citations Open access
Semantic Scholar
A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer
E. Garralda, A. Sukari, N. Lakhani, A. Patnaik +12 more
2022ESMO Open74 citations Open access
Semantic Scholar
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial.
A. Wagner, P. Severson, A. Shields, A. Patnaik +28 more
2021JAMA Oncology41 citations Open access
Semantic Scholar
A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients.
G. Fisher, N. Lakhani, C. Eng, J. Hecht +14 more
202039 citations
Semantic Scholar
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma
K. Beckermann, A. Patnaik, I. Winer, W. Tan +5 more
2024Investigational new drugs37 citations
Semantic Scholar
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
A. Patnaik, T. Yap, H. Chung, M. D. de Miguel +14 more
2020Clinical Cancer Research37 citations Open access
Semantic Scholar
A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.
E. Garralda, A. Sukari, N. Lakhani, A. Patnaik +11 more
202134 citations
Semantic Scholar
Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors
Y. Murciano-Goroff, R. Heist, Y. Kuboki, T. Koyama +21 more
2023Cancer Research31 citations
Semantic Scholar
525O A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies
G. Ku, J. Bendell, A. Tolcher, S. Hurvitz +14 more
2020Annals of Oncology29 citations Open access
Semantic Scholar
A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer
C. Kollmannsberger, C. Britten, A. Olszanski, J. Walker +6 more
2021Investigational new drugs28 citations
Semantic Scholar
O82 A phase 1 dose escalation study of PRS-343, a HER2/4–1BB bispecific molecule, in patients with HER2-positive malignancies
S. Piha-Paul, J. Bendell, A. Tolcher, S. Hurvitz +14 more
2020Journal of Immunotherapy for Cancer28 citations Open access
Semantic Scholar
A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.
N. Lakhani, A. Patnaik, J. Liao, J. Moroney +12 more
202027 citations
Semantic Scholar
209P Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors
S. Klempner, M. Beeram, D. Sabanathan, A. Chan +13 more
2021Annals of Oncology26 citations Open access
Semantic Scholar
First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors
D. Mahalingam, W. Harb, A. Patnaik, Andrea J. Bullock +9 more
2024Communications Medicine25 citations Open access
Semantic Scholar
Results of a first-in-human phase I study of SRF231, a fully human, high-affinity anti-CD47 antibody.
A. Patnaik, A. Spreafico, Alison M. Paterson, Marisa O. Peluso +8 more
202024 citations
Semantic Scholar
Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study.
A. Hollebecque, Y. Kuboki, Y. Murciano-Goroff, R. Yaeger +14 more
2024Journal of Clinical Oncology19 citations
Semantic Scholar
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial
A. Patnaik, G. Weiss, D. Rasco, Lisa Blaydorn +8 more
2021Cancer Chemotherapy and Pharmacology19 citations Open access
Semantic Scholar
Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer
D. Hong, A. Gopal, A. Shoushtari, S. Patel +11 more
2022Frontiers in Immunology18 citations Open access
Semantic Scholar
Reversible HER2 antibody-drug conjugate-induced ocular toxicity.
Anushree Sharma, Kamran M. Riaz, Mohsain S. Gill, A. Patnaik +8 more
2021Canadian Journal of Ophthalmology-journal Canadien D Ophtalmologie17 citations
Semantic Scholar
295 First-in-human Phase I trial of IBI188, an anti-CD47 targeting monoclonal antibody, in patients with advanced solid tumors and lymphomas
N. Lakhani, M. Orloff, S. Fu, Ying Liu +6 more
202016 citations Open access
Semantic Scholar
SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001).
A. Hollebecque, Juanita Lopez, S. Piha-Paul, A. Dowlati +11 more
2023Journal of Clinical Oncology11 citations
Semantic Scholar
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies
J. Berlin, A. Tolcher, C. Ding, J. Whisenant +8 more
2022Investigational new drugs11 citations
Semantic Scholar
Abstract PR006: Initial results from first-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in biomarker-selected solid tumors
J. Rodon, N. Yamamoto, Toshihiko Doi, F. Ghiringhelli +16 more
2023Molecular Cancer Therapeutics10 citations Open access
Semantic Scholar
First-in-human study of SRF388, a first-in-class IL-27 targeting antibody, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.
A. Naing, C. Mantia, D. Morgensztern, Tae-Yong Kim +16 more
2022Journal of Clinical Oncology10 citations
Semantic Scholar
COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies (NCT03667716).
D. Vaena, G. Fleming, B. Chmielowski, Manish R. Sharma +11 more
202110 citations
Semantic Scholar
135P First-in-human phase I trial of SRF617, a potent inhibitor of CD39 activity, as monotherapy or in combination, in patients (pts) with advanced solid tumors
A. Patnaik, I. Mehmi, J. Strauss, Yangang Xing +12 more
2021Annals of Oncology10 citations Open access
Semantic Scholar
Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors
A. Patnaik, S. Gadgeel, K. Papadopoulos, D. Rasco +8 more
2022Targeted oncology9 citations
Semantic Scholar
Abstract OT-09-03: EMBER: A phase 1a/b trial of LY3484356, a novel, oral selective estrogen-receptor degrader (SERD), in advanced ER+ breast cancer and endometroid endometrial cancer
E. Lim, M. Beeram, A. Prawira, A. Patnaik +4 more
20219 citations
Semantic Scholar
First-in-human phase 1/1b expansion of PMD-026, an oral RSK inhibitor, in patients with metastatic triple-negative breast cancer.
M. Beeram, P. Chalasani, Judy S. Wang, L. Mina +12 more
20218 citations
Semantic Scholar
477 COM902 (Anti-TIGIT antibody) monotherapy – preliminary evaluation of safety, tolerability, pharmacokinetics and receptor occupancy in patients with advanced solid tumors (NCT04354246)
E. Dumbrava, D. Rasco, A. Patnaik, D. Vaena +8 more
2021Journal for ImmunoTherapy of Cancer8 citations Open access
Semantic Scholar
481P A phase I first-in-human study of XL092 in patients (pts) with locally advanced or metastatic solid tumors: Results from dose-escalation of XL092 alone and in combination with atezolizumab
M. R. Sharma, V. Subbiah, G. Shapiro, S. Pål +8 more
2022Annals of Oncology7 citations Open access
Semantic Scholar
Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.
M. Villalona-Calero, A. Patnaik, R. Maki, B. O'Neil +16 more
2022Journal of Clinical Oncology6 citations
Semantic Scholar
957 NKTR-255+cetuximab in patients with solid tumors: interim safety and efficacy results from the phase 1b dose-escalation study
M. Altan, A. Patnaik, M. Barve, L. Dunn +16 more
2021Journal for ImmunoTherapy of Cancer6 citations Open access
Semantic Scholar
374 A first-in-human Phase 1/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors
D. Mahalingam, W. Harb, A. Patnaik, S. Ulahannan +15 more
20206 citations Open access
Semantic Scholar
Abstract CT084: A phase 1 study of LY4101174 (ETx-22), an antibody-drug conjugate targeting nectin-4, in patients with advanced or metastatic urothelial cancer and other solid tumors (trial in progress)
J. Rosenberg, R. Sabatier, Armelle Viceneux, T. de la Motte Rouge +22 more
2024Cancer Research5 citations
Semantic Scholar
LBA63 PRESTO: A phase III, open-label study of androgen annihilation in patients (pts) with high-risk biochemically relapsed prostate cancer (AFT-19)
R. Aggarwal, G. Heller, D. Hillman, Han Xiao +16 more
2022Annals of Oncology5 citations Open access
Semantic Scholar
EP08.02-116 Design of a Phase 1 Study of AMG 193, an MTA-Cooperative PRMT5 Inhibitor, in Patients with Advanced MTAP-Null Solid Tumors
M. Calero, A. Patnaik, R. Maki, B. O'Neil +16 more
2022Journal of Thoracic Oncology5 citations Open access
Semantic Scholar
Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibody–drug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V-001, trial in progress).
A. Patnaik, J. Call, A. Spreafico, L. Nabell +3 more
2022Journal of Clinical Oncology5 citations
Semantic Scholar
Results of a phase 1 study of SRF388, a first-in-human, first-in-class, high-affinity anti-IL-27 antibody in advanced solid tumors.
A. Patnaik, D. Morgensztern, C. Mantia, N. Tannir +10 more
20215 citations
Semantic Scholar
A phase 1 study of SGN-B6A, an antibody-drug conjugate targeting integrin beta-6, in patients with advanced solid tumors (SGNB6A-001, Trial in Progress).
A. Patnaik, E. Calvo, S. Piha-Paul, A. Hollebecque +7 more
20215 citations
Semantic Scholar
478 COM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab – preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors (NCT04570839)
E. Dumbrava, Manish R. Sharma, G. Fleming, K. Papadopoulos +10 more
2021Journal for ImmunoTherapy of Cancer5 citations Open access
Semantic Scholar
731 A first-in-human trial of an integrin beta-6 targeted antibody-drug conjugate (ADC), SGN-B6A, in patients with advanced solid tumors: interim results of a phase 1 study (SGNB6A-001)
A. Hollebecque, Juanita Lopez, S. Piha-Paul, A. Dowlati +11 more
2022Regular and Young Investigator Award Abstracts4 citations Open access
Semantic Scholar
A phase 1 first-in-human study of XL092 administered alone or in combination with immune checkpoint inhibitors (ICIs) in patients (pts) with inoperable locally advanced or metastatic solid tumors: Description of genitourinary (GU) expansion cohorts.
Manish R. Sharma, V. Subbiah, G. Shapiro, S. Pal +8 more
2022Journal of Clinical Oncology4 citations
Semantic Scholar
Phase 1b/2a study of PLX2853, a small molecule BET inhibitor, in subjects with advanced solid tumors and lymphoma.
Michael Gordon, R. Carvajal, A. Spira, Marilyn Huang +11 more
20214 citations
Semantic Scholar
Abstract P4-01-35: A Phase 1 Study of the Oral CDK7 Inhibitor XL102 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors (QUARTZ-101): Initial Results From the Dose-Escalation Stage
A. Patnaik, M. Barve, M. Bhave, V. Subbiah +5 more
2023Cancer Research3 citations
Semantic Scholar
ARC-20: A phase 1 dose-escalation and dose-expansion study to investigate the safety, tolerability, and pharmacology of HIF-2α inhibitor AB521 monotherapy in patients with clear cell renal cell carcinoma and other solid tumors.
T. Choueiri, B. Garmezy, E. Paterson, Mohammad Ghasemi +4 more
2023Journal of Clinical Oncology3 citations Open access
Semantic Scholar
A phase 1a dose-escalation study of PY159, a monoclonal antibody targeting TREM1 (triggering receptor expressed on myeloid cells 1).
I. Winer, A. Patnaik, M. Barve, S. Kummar +12 more
2023Journal of Clinical Oncology3 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Beeram×6
Invite
M. Beeram — researcher profile on SciRah
S. Piha-Paul×6
Invite
S. Piha-Paul — researcher profile on SciRah
D. Rasco×6
Invite
D. Rasco — researcher profile on SciRah
N. Lakhani×5
Invite
N. Lakhani — researcher profile on SciRah

×5

Invite

A. Hollebecque — researcher profile on SciRah

Invite

E. Hamilton — researcher profile on SciRah

Invite

E. Calvo — researcher profile on SciRah

M. D. de Miguel×4

Invite

M. D. de Miguel — researcher profile on SciRah

Invite

A. Tolcher — researcher profile on SciRah

Invite

J. Bendell — researcher profile on SciRah

Invite

A. Dowlati — researcher profile on SciRah

Manish R. Sharma×4

Invite

Manish R. Sharma — researcher profile on SciRah